In a first-in-human study, researchers at The University of Texas MD Anderson Cancer Center observed strong responses and early signs of antitumor activity in patients with difficult-to-treat non-Hodgkin lymphomas who received the novel cell therapy RB-1355. The therapy was effective for those who have relapsed after multiple treatments or no longer responded to standard-of-care options, such as CAR T cell therapy.
This article was originally published on MedicalXpress.com

